China's inactivated COVID-19 vaccine candidate has entered the phase-3 clinical trial in the United Arab Emirates, according to Sinopharm's China National Biotec Group (CNBG) on Tuesday, 23 June.
This is the first company in China to conduct an overseas clinical trial of the COVID-19 vaccine, state broadcaster CGTN reported.
The vaccine, developed by the Wuhan Institute of Biological Products under CNBG affiliated to Sinopharm, has shown promising results in terms of both safety and efficacy in phase-1 and phase-2 clinical trials.
The CNBG is actively promoting overseas cooperation in the phase-3 clinical trial of the vaccine.
This is primarily because there are currently not enough COVID-19 patients in China required for a phase-3 clinical trial, according to experts.
The company has already secured the intention of the cooperation of several firms and research institutions from different countries.
(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)